Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study
- 1 September 2013
- journal article
- research article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 1 (7) , 524-533
Abstract
No abstract availableKeywords
Funding Information
- Novartis
This publication has 27 references indexed in Scilit:
- The role of bronchodilator treatment in the prevention of exacerbations of COPDEuropean Respiratory Journal, 2012
- IndacaterolDrugs, 2012
- Tiotropium Bromide Inhalation PowderDrugs, 2012
- Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEuropean Respiratory Journal, 2011
- Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropiumRespiratory Research, 2010
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH StudyAmerican Journal of Respiratory and Critical Care Medicine, 2008
- COPD exacerbations {middle dot} 3: PathophysiologyThorax, 2006
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003